Nuformix plc (LON:NFX – Get Free Report) traded up 8.7% during trading on Wednesday . The company traded as high as GBX 0.09 ($0.00) and last traded at GBX 0.09 ($0.00). 3,331,248 shares changed hands during trading, a decline of 96% from the average session volume of 74,219,031 shares. The stock had previously closed at GBX 0.08 ($0.00).
Nuformix Trading Up 3.8 %
The company has a market cap of £1.02 million, a P/E ratio of -2.52 and a beta of 1.22. The company’s fifty day moving average is GBX 0.07 and its 200 day moving average is GBX 0.09.
Nuformix (LON:NFX – Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- 3 Fintech Stocks With Good 2021 Prospects
- Alphabet’s Pullback Just Opened a Window for Smart Investors
- How to Invest in Small Cap Stocks
- Moderna: A Generational Opportunity for Investors in 2025
- What Are Some of the Best Large-Cap Stocks to Buy?
- Buffett Just Dumped His S&P 500 Holdings—What It Means for You
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
